Abstract
Forty patients with chronic respiratory infections were randomly assigned to 2 groups to compare the effect of once daily administration of 300 mg each and 3 times daily administration of 600 mg each of ofloxacin (OFLX). Twenty patients were administered with 300 mg OFLX a day and 18 cases received 600 mg. The number of underlying diseases in the 300 mg group was greater than that in the 600 mg group. The ratios of general amelioration of clinical symptoms were 80.0% in the 300 mg group and 88.9% in the 600 mg group. For bacteriological effects, the eradication rate was 80.0% in the 300 mg group and it was 84.6% in the 600 mg. The incidence of side effects in the 300 mg group was 0% and that of the 600 mg group was 5.6% (1 patient) but the symptom was mild. The incidence of abnormal laboratory test results was 15.0% in the 300 mg group and it was 11.2% in the 600 mg group, but all of these abnormalities were slight and transient. The safety rates in the 300 mg and the 600 mg groups were 95.0% and 94.4%, respectively. Efficacy rates in the 300 mg and the 600 mg groups were 80.0% and 88.9%, respectively. There was no statistically significant difference in all the results between the 2 treatment groups, and both the treatments were highly effective. From the above results, we consider that once daily administration of 300 mg is a useful therapy in respiratory tract infections.
| Original language | English |
|---|---|
| Pages (from-to) | 60-66 |
| Number of pages | 7 |
| Journal | Japanese Journal of Antibiotics |
| Volume | 46 |
| Issue number | 1 |
| Publication status | Published - 1993 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
Clinical studies of ofloxacin 300 mg once a day administration in chronic respiratory tract infections. / Fukuhara, H.; Kusano, Nobuchika; Irabu, Y.; Shigeno, Y.; Saito, A.; Nakamura, H.; Horimoto, S.; Shimozi, T.; Miyagi, M.; Inadome, J.; Miyaguni, T.; Kumai, M.
In: Japanese Journal of Antibiotics, Vol. 46, No. 1, 1993, p. 60-66.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical studies of ofloxacin 300 mg once a day administration in chronic respiratory tract infections
AU - Fukuhara, H.
AU - Kusano, Nobuchika
AU - Irabu, Y.
AU - Shigeno, Y.
AU - Saito, A.
AU - Nakamura, H.
AU - Horimoto, S.
AU - Shimozi, T.
AU - Miyagi, M.
AU - Inadome, J.
AU - Miyaguni, T.
AU - Kumai, M.
PY - 1993
Y1 - 1993
N2 - Forty patients with chronic respiratory infections were randomly assigned to 2 groups to compare the effect of once daily administration of 300 mg each and 3 times daily administration of 600 mg each of ofloxacin (OFLX). Twenty patients were administered with 300 mg OFLX a day and 18 cases received 600 mg. The number of underlying diseases in the 300 mg group was greater than that in the 600 mg group. The ratios of general amelioration of clinical symptoms were 80.0% in the 300 mg group and 88.9% in the 600 mg group. For bacteriological effects, the eradication rate was 80.0% in the 300 mg group and it was 84.6% in the 600 mg. The incidence of side effects in the 300 mg group was 0% and that of the 600 mg group was 5.6% (1 patient) but the symptom was mild. The incidence of abnormal laboratory test results was 15.0% in the 300 mg group and it was 11.2% in the 600 mg group, but all of these abnormalities were slight and transient. The safety rates in the 300 mg and the 600 mg groups were 95.0% and 94.4%, respectively. Efficacy rates in the 300 mg and the 600 mg groups were 80.0% and 88.9%, respectively. There was no statistically significant difference in all the results between the 2 treatment groups, and both the treatments were highly effective. From the above results, we consider that once daily administration of 300 mg is a useful therapy in respiratory tract infections.
AB - Forty patients with chronic respiratory infections were randomly assigned to 2 groups to compare the effect of once daily administration of 300 mg each and 3 times daily administration of 600 mg each of ofloxacin (OFLX). Twenty patients were administered with 300 mg OFLX a day and 18 cases received 600 mg. The number of underlying diseases in the 300 mg group was greater than that in the 600 mg group. The ratios of general amelioration of clinical symptoms were 80.0% in the 300 mg group and 88.9% in the 600 mg group. For bacteriological effects, the eradication rate was 80.0% in the 300 mg group and it was 84.6% in the 600 mg. The incidence of side effects in the 300 mg group was 0% and that of the 600 mg group was 5.6% (1 patient) but the symptom was mild. The incidence of abnormal laboratory test results was 15.0% in the 300 mg group and it was 11.2% in the 600 mg group, but all of these abnormalities were slight and transient. The safety rates in the 300 mg and the 600 mg groups were 95.0% and 94.4%, respectively. Efficacy rates in the 300 mg and the 600 mg groups were 80.0% and 88.9%, respectively. There was no statistically significant difference in all the results between the 2 treatment groups, and both the treatments were highly effective. From the above results, we consider that once daily administration of 300 mg is a useful therapy in respiratory tract infections.
UR - http://www.scopus.com/inward/record.url?scp=0027417257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027417257&partnerID=8YFLogxK
M3 - Article
C2 - 8455332
AN - SCOPUS:0027417257
VL - 46
SP - 60
EP - 66
JO - The Journal of antibiotics. Ser. B
JF - The Journal of antibiotics. Ser. B
SN - 0368-2781
IS - 1
ER -